12:00 AM
 | 
Jul 07, 2008
 |  BioCentury  |  Strategy

Flurizan chronicles

Flurizan chronicles

Myriad Genetics (NASDAQ:MYGN) was up 10% on the week despite discontinuing development of its lead drug candidate. The stock fell 5% last Monday, when the company said it would discontinue development of Flurizan after the R-enantiomer of flurbiprofen missed the co-primary endpoints in a U.S. Phase III trial to treat mild Alzheimer’s disease (AD). Below are selected Flurizan-related events tracked against the company’s weekly stock...

Read the full 311 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >